Practice Patterns for Prevention of Chemotherapy-Induced Nausea and Vomiting and Antiemetic Guideline Adherence Based on Real-World Prescribing Data

Matti Aapro(Clinique de Genolier), Karin Jordan(Heidelberg University), Yolanda Escobar(Hospital Universitario Virgen de las Nieves), Florian Scotté(Université Paris-Saclay), Danielle Bell, A. Franceschetti(Ipsos (United Kingdom)), Richard Berman(The Christie NHS Foundation Trust), Luigi Celio
The Oncologist
February 8, 2021
10.1002/onco.13716
Cited by 68

Related Papers

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k
A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer
|Annals of Oncology|2013|351
A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy
|Annals of Oncology|2006|340